$OXIS CEO Anthony Cataldo to Participate in Business of Biotech 2015

TAMPA, Fla., April 14, 2015 /PRNewswire/ –Oxis International, Inc. (OXIS) (OXI.PA) a biotechnology company focused on cancer therapy development and commercialization, announced today Oxis CEO Tony Cataldo has accepted an invitation to participate in the Business of Biotech 2015 conference on Friday, April 17 at the Moffitt Cancer Center in Tampa, Florida.

Business of Biotech 2015: Collaborate to Innovate is the headline of the ninth annual Business of Biotech Conference. Former ABC news correspondent and member of the Moffitt Board of Advisors will conduct a conversation with keynote speaker Henri Termeer, former CEO, Chairman, and President of Genzyme. Genzyme was recently purchased by Sanofi for over $20 billion.

Mr. Cataldo will be discussing Raising Funds, What’s Trending Now? Fundraising strategies and latest trends from emerging life science companies? Also participating on the panel will be executives from Cvergenx, Lion Biotechnologies, Metastat and Signal Genetics.

Oxis Chairman and CEO Tony Cataldo stated, “I look forward to being a part of the Moffitt  Biotech Conference. Oxis is now in a position to make a major move forward with its high value technologies which are at the leading edge of immunotherapeutics in the very large cancer therapies markets.”

Contact

Jonathan Barkman
Riverview Capital Enterprises
1275 Glenlivet Dr Ste 100
Allentown, PA 18106
office  866-845-0105
fax     484-224-2999

ABOUT OXIS BIOTECH, INC. – OXIS is a biotech company that develops and commercializes innovative drugs of therapeutic molecules including cannabinoids, which are focused on several cancer indications. Oxis address the clinical shortcomings of existing commercial products in related fields. OXIS has formed relationships with some of the world’s leading cannabinoid researchers and institutions to advance its technologies.

Forward-Looking Statements Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/oxis-biotech-inc-announces-ceo-anthony-cataldo-to-participate-in-business-of-biotech-2015-at-the-moffitt-cancer-center-300065284.html